Jung Jinhong, Kim Su Ssan, Ahn Seung Do, Lee Sang-Wook, Ahn Sei-Hyun, Son Byung Ho, Lee Jong Won, Choi Eun Kyung
Department of Radiation Oncology, Kyung Hee University Medical Center, Kyung Hee University School of Medicine, Seoul, Korea.
Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
J Breast Cancer. 2015 Jun;18(2):167-72. doi: 10.4048/jbc.2015.18.2.167. Epub 2015 Jun 26.
The aim of this study was to investigate the prognosis, patterns of failure, and prognostic factors for breast cancer patients with pathologically proven synchronous ipsilateral supraclavicular lymph node (ISCLN) metastases.
We reviewed the records of breast cancer patients with pathologically proven ISCLN metastases. Local aggressive treatment was defined as treatment including surgery, axillary lymph node dissection (ALND), ISCLN excision, radiotherapy (RT), and chemotherapy.
A total of 111 patients were included. The 5-year overall survival (OS) and disease-free survival (DFS) rates were 64.2% and 56.2%, respectively. On univariate analysis, RT, ALND, trastuzumab treatment, hormone receptor (HR) status, and local aggressive treatment were identified as significant factors for OS. The 5-year OS for 73 patients who received local aggressive treatment was superior to that of 38 patients who received nonaggressive treatment (70.9% vs. 49.3%, p=0.036). Multivariate analysis showed that RT, HR status, and trastuzumab were significant variables for the 5-year OS and DFS.
Multimodality treatment with surgery, taxane-based chemotherapy, hormone therapy, and RT is strongly recommended for breast cancer patients with synchronous ISCLN metastases.
本研究旨在调查经病理证实患有同侧锁骨上淋巴结（ISCLN）同步转移的乳腺癌患者的预后、失败模式及预后因素。
我们回顾了经病理证实患有ISCLN转移的乳腺癌患者的记录。局部积极治疗定义为包括手术、腋窝淋巴结清扫（ALND）、ISCLN切除、放疗（RT）和化疗的治疗。
共纳入111例患者。5年总生存率（OS）和无病生存率（DFS）分别为64.2%和56.2%。单因素分析显示，放疗、ALND、曲妥珠单抗治疗、激素受体（HR）状态和局部积极治疗是OS的显著因素。73例接受局部积极治疗的患者的5年OS优于38例接受非积极治疗的患者（70.9%对49.3%，p =
